Microbot Medical Inc. announced the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model. As previously announced on December 7, 2023, the study was conducted by three leading interventional radiologists that utilized the LIBERTY Endovascular Robotic Surgical System to perform a total of 96 robotic navigations. Target vessels with surrounding tissue were examined and evaluated microscopically after they were subjected to procedures using a range of commercially available intravascular catheterization devices controlled and manipulated via the LIBERTY Endov vascular Robotic Surgical System.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.975 USD | +3.71% | +7.81% | -39.02% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-39.02% | 13.54M | |
+38.44% | 50.93B | |
-0.34% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.83% | 26.02B | |
-22.48% | 18.9B | |
+8.42% | 13.21B | |
+24.84% | 12.17B | |
+30.09% | 12.16B |
- Stock Market
- Equities
- MBOT Stock
- News Microbot Medical Inc.
- Microbot Medical Announces Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Met